Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibitor development and mortality in non-severe hemophilia A.
Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, Mazzucconi MG, Tagliaferri A, Siegmund B, Reitter-Pfoertner SE, van der Bom JG, Fijnvandraat K; INSIGHT Study Group. Eckhardt CL, et al. J Thromb Haemost. 2015 Jul;13(7):1217-25. doi: 10.1111/jth.12990. Epub 2015 Jun 10. J Thromb Haemost. 2015. PMID: 25912309 Free article.
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
Gruppo RA, Malan D, Kapocsi J, Nemes L, Hay CRM, Boggio L, Chowdary P, Tagariello G, von Drygalski A, Hua F, Scaramozza M, Arkin S; Marzeptacog alfa (activated) Study Group Investigators. Gruppo RA, et al. J Thromb Haemost. 2018 Oct;16(10):1984-1993. doi: 10.1111/jth.14247. Epub 2018 Aug 27. J Thromb Haemost. 2018. PMID: 30151972 Free article. Clinical Trial.
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
de Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, Nemes L, Šalek SZ, Shima M, Windyga J, Ehrenforth S, Chuansumrit A; 1804 (adept(TM)1) Investigators. de Paula EV, et al. J Thromb Haemost. 2012 Jan;10(1):81-9. doi: 10.1111/j.1538-7836.2011.04549.x. J Thromb Haemost. 2012. PMID: 22470921 Free article. Clinical Trial.
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.
Mahlangu JN, Weldingh KN, Lentz SR, Kaicker S, Karim FA, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knobe K; adept™2 Investigators. Mahlangu JN, et al. J Thromb Haemost. 2015 Nov;13(11):1989-98. doi: 10.1111/jth.13141. Epub 2015 Oct 13. J Thromb Haemost. 2015. PMID: 26362483 Free article. Clinical Trial.
328 results